Fig. 3 | Scientific Reports

Fig. 3

From: VHL ameliorates arecoline-induced oral submucosal fibrosis by promoting HDAC6 ubiquitination and blocking NF-κB pathway

Fig. 3

VHL enhances HDAC6 ubiquitination and inhibits arecoline -induced BMFs activation. (A) BMFs harboring overexpression of VHL were treated with 100 µg/ml CHX for 2, 4, 6 h. The treated cells were lysed and subjected to WB analysis with the antibodies indicated. The relative ratios of HDAC6/β-actin normalized to one at t = 0 time point were quantified. (B) Overexpressing VHL cells were treated with ALLN for 24 h before being collected for WB. (C) BMFs were transfected with HA-Ubiquitin, Flag-HDAC6, or overexpressing VHL, then immunoprecipitated with anti-Flag beads, followed by immunoblotting. (D) The mRNA level of HDAC6 was analyzed by qPCR. (E) sh-NC and sh-HDAC6 BMFs were treated with arecoline and the gel contraction capacity of sh-NC and sh-HDAC6 cells was measure by collagen contraction assay. (F) The migration capacity was examined by wound healing assay. (G) The protein levels of α-SMA, COL1A1 and FN1 were determined by WB. *P<0.5, **P<0.01, ***P<0.001.

Back to article page